Longeveron® to Report Second Quarter 2025 Financial Results and Host Conference Call on August 13, 2025
Longeveron (NASDAQ: LGVN), a clinical stage regenerative medicine biotech company, will release its Q2 2025 financial results on Wednesday, August 13, 2025 after market close. The company will host a conference call and webcast at 4:30 p.m. ET the same day.
Investors can access the conference call via telephone at 1.877.407.0789 using conference ID 13754295. A webcast replay will be available in the "Events & Presentations" section of Longeveron's website after the conference.
Longeveron (NASDAQ: LGVN), un'azienda biotecnologica specializzata in medicina rigenerativa in fase clinica, pubblicherà i suoi risultati finanziari del secondo trimestre 2025 mercoledì 13 agosto 2025 dopo la chiusura del mercato. La società terrà una conference call e una trasmissione in webcast alle 16:30 ET dello stesso giorno.
Gli investitori potranno partecipare alla conference call telefonando al numero 1.877.407.0789 e utilizzando l'ID conferenza 13754295. Una registrazione del webcast sarà disponibile nella sezione "Eventi e Presentazioni" del sito web di Longeveron dopo la conferenza.
Longeveron (NASDAQ: LGVN), una empresa biotecnológica en etapa clínica especializada en medicina regenerativa, publicará sus resultados financieros del segundo trimestre de 2025 el miércoles 13 de agosto de 2025 después del cierre del mercado. La compañía realizará una conferencia telefónica y una transmisión web a las 4:30 p.m. ET ese mismo día.
Los inversores pueden acceder a la conferencia telefónica llamando al 1.877.407.0789 y usando el ID de conferencia 13754295. Una repetición de la transmisión web estará disponible en la sección "Eventos y Presentaciones" del sitio web de Longeveron después de la conferencia.
Longeveron (NASDAQ: LGVN)은 임상 단계 재생 의학 바이오테크 회사로, 2025년 2분기 재무 실적을 2025년 8월 13일 수요일 장 마감 후 발표할 예정입니다. 회사는 같은 날 동부 표준시 오후 4시 30분에 컨퍼런스 콜과 웹캐스트를 진행합니다.
투자자들은 1.877.407.0789번으로 전화하여 회의 ID 13754295를 사용해 컨퍼런스 콜에 참여할 수 있습니다. 컨퍼런스 후 Longeveron 웹사이트의 "이벤트 및 발표" 섹션에서 웹캐스트 녹화 영상을 시청할 수 있습니다.
Longeveron (NASDAQ : LGVN), une société biotechnologique en phase clinique spécialisée en médecine régénérative, publiera ses résultats financiers du deuxième trimestre 2025 le mercredi 13 août 2025 après la clôture du marché. La société organisera une conférence téléphonique et une webdiffusion à 16h30 ET le même jour.
Les investisseurs peuvent accéder à la conférence téléphonique en appelant le 1.877.407.0789 et en utilisant l'ID de conférence 13754295. Une rediffusion de la webdiffusion sera disponible dans la section "Événements & Présentations" du site web de Longeveron après la conférence.
Longeveron (NASDAQ: LGVN), ein biotechnologisches Unternehmen im klinischen Stadium der regenerativen Medizin, wird seine Finanzergebnisse für das zweite Quartal 2025 am Mittwoch, den 13. August 2025 nach Börsenschluss veröffentlichen. Das Unternehmen wird am selben Tag um 16:30 Uhr ET eine Telefonkonferenz und eine Webcast-Veranstaltung abhalten.
Investoren können über die Telefonnummer 1.877.407.0789 mit der Konferenz-ID 13754295 an der Telefonkonferenz teilnehmen. Eine Aufzeichnung des Webcasts wird nach der Konferenz im Bereich "Events & Präsentationen" auf der Website von Longeveron verfügbar sein.
- None.
- None.
MIAMI, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening, rare pediatric and chronic aging-related conditions, today announced that it will report second quarter 2025 financial results and provide a business update on Wednesday, August 13, 2025 after the U.S. financial markets close. The Company will host a conference call and webcast the same day at 4:30 p.m. ET.
| Conference Call and Webcast Details: | |
| Conference Call Number: | 1.877.407.0789 |
| Conference ID: | 13754295 |
| Call meTM Feature: | Click Here |
| Webcast: | Click Here |
An archived replay of the webcast will be available on the “Events & Presentations” section of the Company’s website following the conference.
About Longeveron Inc.
Longeveron is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. The Company’s lead investigational product is laromestrocel (Lomecel-B™), an allogeneic mesenchymal stem cell (MSC) therapy product isolated from the bone marrow of young, healthy adult donors. Laromestrocel has multiple potential mechanisms of action encompassing pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas. Longeveron is currently pursuing four pipeline indications: hypoplastic left heart syndrome (HLHS), Alzheimer’s disease, Pediatric Dilated Cardiomyopathy (DCM), and Aging-related Frailty. Laromestrocel development programs have received five distinct and important FDA designations: for the HLHS program - Orphan Drug designation, Fast Track designation, and Rare Pediatric Disease designation; and, for the AD program - Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation. For more information, visit www.longeveron.com or follow Longeveron on LinkedIn, X, and Instagram.
Investor and Media Contact:
Derek Cole
Investor Relations Advisory Solutions
derek.cole@iradvisory.com
FAQ
When will Longeveron (LGVN) report Q2 2025 earnings?
What time is Longeveron's Q2 2025 earnings call?
How can I access Longeveron's Q2 2025 earnings call?
What does Longeveron (LGVN) specialize in?
